Search Results - "REARDON, D. A"

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas by van den Bent, MJ, Prof, Wefel, JS, PhD, Schiff, D, MD, Taphoorn, MJB, Prof, Jaeckle, K, MD, Junck, L, MD, Armstrong, T, PhD, Choucair, A, MD, Waldman, AD, PhD, Gorlia, T, MSc, Chamberlain, M, MD, Baumert, BG, MD, Vogelbaum, MA, MD, Macdonald, DR, MD, Reardon, DA, MD, Wen, PY, Prof, Chang, SM, Prof, Jacobs, AH, Prof

“…Summary Although low-grade gliomas (LGG) have a less aggressive course than do high-grade gliomas, the outcome of these tumours is ultimately fatal in most…”
Get full text

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study by Reardon, D A, Desjardins, A, Vredenburgh, J J, Gururangan, S, Sampson, J H, Sathornsumetee, S, McLendon, R E, Herndon, J E, Marcello, J E, Norfleet, J, Friedman, A H, Bigner, D D, Friedman, H S

“…Background: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. Methods: A total of 59…”
Get full text

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients by Reardon, D A, Herndon, J E, Peters, K B, Desjardins, A, Coan, A, Lou, E, Sumrall, A L, Turner, S, Lipp, E S, Sathornsumetee, S, Rich, J N, Sampson, J H, Friedman, A H, Boulton, S T, Bigner, D D, Friedman, H S, Vredenburgh, J J

“…Background: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial…”
Get full text

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma by Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z

“…Background: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not…”
Get full text

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study by Schuster, James, Lai, Rose K, Recht, Lawrence D, Reardon, David A, Paleologos, Nina A, Groves, Morris D, Mrugala, Maciej M, Jensen, Randy, Baehring, Joachim M, Sloan, Andrew, Archer, Gary E, Bigner, Darell D, Cruickshank, Scott, Green, Jennifer A, Keler, Tibor, Davis, Thomas A, Heimberger, Amy B, Sampson, John H

“…The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term…”
Get full text

Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma by George, E, Flagg, E, Chang, K, Bai, H X, Aerts, H J, Vallières, M, Reardon, D A, Huang, R Y

“…Imaging assessment of an immunotherapy response in glioblastoma is challenging due to overlap in the appearance of treatment-related changes with tumor…”
Get full text

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges by Reardon, David A, Wen, Patrick Y, Mellinghoff, Ingo K

“…Epidermal growth factor receptor (EGFR) has emerged as a highly attractive therapeutic target in glioblastoma (GBM) based on its high frequency of gene…”
Get full text

Medical management of brain tumors and the sequelae of treatment by Schiff, David, Lee, Eudocia Q, Nayak, Lakshmi, Norden, Andrew D, Reardon, David A, Wen, Patrick Y

“…Patients with malignant brain tumors are prone to complications that negatively impact their quality of life and sometimes their overall survival as well…”
Get full text

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma by Aizer, Ayal A, Arvold, Nils D, Catalano, Paul, Claus, Elizabeth B, Golby, Alexandra J, Johnson, Mark D, Al-Mefty, Ossama, Wen, Patrick Y, Reardon, David A, Lee, Eudocia Q, Nayak, Lakshmi, Rinne, Mikael L, Beroukhim, Rameen, Weiss, Stephanie E, Ramkissoon, Shakti H, Abedalthagafi, Malak, Santagata, Sandro, Dunn, Ian F, Alexander, Brian M

“…The impact of adjuvant radiation in patients with atypical meningioma remains poorly defined. We sought to determine the impact of adjuvant radiation therapy…”
Get full text

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study by Yung, W.K. Alfred, Vredenburgh, James J., Cloughesy, Timothy F., Nghiemphu, Phioanh, Klencke, Barbara, Gilbert, Mark R., Reardon, David A., Prados, Michael D.

“…Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in glioblastoma. We evaluated erlotinib efficacy in patients with…”
Get full text

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study by Simonelli, M., Garralda, E., Eskens, F., Gil-Martin, M., Yen, C.-J., Obermannova, R., Chao, Y., Lonardi, S., Melichar, B., Moreno, V., Yu, M.-L., Bongiovanni, A., Calvo, E., Rottey, S., Machiels, J.-P., Gonzalez-Martin, A., Paz-Ares, L., Chang, C.-L., Mason, W., Lin, C.-C., Reardon, D.A., Vieito, M., Santoro, A., Meng, R., Abbadessa, G., Menas, F., Lee, H., Liu, Q., Combeau, C., Ternes, N., Ziti-Ljajic, S., Massard, C.

“…The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors…”
Get full text

Clinical trial end points for high-grade glioma: the evolving landscape by Reardon, David A., Galanis, Evanthia, DeGroot, John F., Cloughesy, Timothy F., Wefel, Jeffrey S., Lamborn, Kathleen R., Lassman, Andrew B., Gilbert, Mark R., Sampson, John H., Wick, Wolfgang, Chamberlain, Marc C., Macdonald, David R., Mehta, Minesh P., Vogelbaum, Michael A., Chang, Susan M., Van den Bent, Martin J., Wen, Patrick Y.

“…To review the strengths and weaknesses of primary and auxiliary end points for clinical trials among patients with high-grade glioma (HGG). Recent advances in…”
Get full text

Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization by REARDON, D. A, MICHALKIEWICZ, E, KUN, L. E, SHAPIRO, D. N, LOOK, A. T, BOYETT, J. M, SUBLETT, J. E, ENTREKIN, R. E, RAGSDALE, S. T, VALENTINE, M. B, BEHM, F. G, LI, H, HEIDEMAN, R. L

“…We analyzed 27 samples of primary medulloblastoma, using comparative genomic hybridization and a novel statistical approach to evaluate chromosomal regions for…”
Get full text

Comparison of Lumbar and Shunt Cerebrospinal Fluid Specimens for Cytologic Detection of Leptomeningeal Disease in Pediatric Patients With Brain Tumors by Gajjar, A, Fouladi, M, Walter, A W, Thompson, S J, Reardon, D A, Merchant, T E, Jenkins, J J, Liu, A, Boyett, J M, Kun, L E, Heideman, R L

“…Leptomeningeal disease (LMD) significantly affects the prognosis and treatment of pediatric patients with primary CNS tumors. Cytologic examination of lumbar…”
Get full text

Pediatric choroid plexus neoplasms by Chow, E, Reardon, D A, Shah, A B, Jenkins, J J, Langston, J, Heideman, R L, Sanford, R A, Kun, L E, Merchant, T E

“…Choroid plexus tumors (CPT) are rare childhood neoplasms. The relatively small number of reported cases and the controversies surrounding the clinical and…”
Get more information

Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma by Reardon, D A, Jenkins, J J, Sublett, J E, Burger, P C, Kun, L K

“…The large cell (LC) subtype is a recently described histologic variant of medulloblastoma (Mb) associated with a rapid and aggressive clinical course. We…”
Get more information

Bithalamic involvement predicts poor outcome among children with thalamic glial tumors by Reardon, D A, Gajjar, A, Sanford, R A, Heideman, R L, Walter, A W, Thompson, S J, Merchant, T E, Li, H, Jenkins, J J, Langston, J, Boyett, J M, Kun, L E

“…Clinical features and treatment of 36 consecutive pediatric patients with thalamic glial tumors confirmed by histology and characterized by neuroimaging were…”
Get more information

High-grade pediatric spinal cord tumors by Merchant, T E, Nguyen, D, Thompson, S J, Reardon, D A, Kun, L E, Sanford, R A

“…Our institutional experience with high-grade pediatric spinal cord tumors includes 11 children treated during the period of 1981-1997. All patients underwent a…”
Get more information

Malignant evolution of choroid plexus papilloma by Chow, E, Jenkins, J J, Burger, P C, Reardon, D A, Langston, J W, Sanford, R A, Heideman, R L, Kun, L E, Merchant, T E

“…Choroid plexus tumors are rare CNS neoplasms. The distinction between choroid plexus papilloma (CPP) and choroid plexus carcinoma (CPC) is made on the basis of…”
Get more information

Detection of Circulating Donor White Blood Cells in Patients Receiving Multiple Transfusions by Adams, Paul T., Davenport, Robertson D., Reardon, David A., Roth, Mark S.

“…Significant morbidities are associated with the routine administration of blood products. Although the exact etiology of these complications may be unknown,…”
Get full text